Redefining Risk of Recurrence: Latest advances with CDK4/6 inhibitors in HR+/HER2− early breast cancer

Michael Gnant have been the Co-Chair of the highly successful, annual St Gallen Breast Cancer Conference in Vienna, and chaired a session about the latest advances of CDK4/6 inhibitor treatment in HR+/HER2− early breast cancer, focusing on risk of recurrence.